Document:

Document

Exhibit 10.26.15

AMENDMENT NUMBER FOURTEEN TO THE 
METLIFE LEADERSHIP DEFERRED COMPENSATION PLAN
(As amended and restated effective with respect to salary and Cash Incentive Compensation January 1, 2005 and with respect to Stock Compensation, April 15, 2005)

The MetLife Leadership Deferred Compensation Plan (“the Plan”) is hereby amended, effective as of April 7, 2021, as follows:

I.     Section 19 is amended by adding the following as the second paragraph thereof:

Pursuant to Treasury Regulation sec. 1.409A-3(j)(4)(ix)(B), and notwithstanding any provision of the Plan to the contrary, (1) effective as of the MPC Closing Date (as defined in Section 22.12), the Plan shall be liquidated and terminated with respect to (x) each Participant who is employed by Metropolitan Property and Casualty Insurance Company as of both the MPC Closing Date and the following day and (y) each Participant who is an employee of MetLife Group, Inc. who receives an offer of employment with Farmers Group, Inc. or any subsidiary or affiliate thereof as of the MPC Closing Date, and (2) within 12 months of the MPC Closing Date and on such date or dates as shall be determined by the Plan Administrator, the entire accrued benefit of each such Participant under the Plan shall be fully paid to such Participant.
II.     Section 22.12 shall be replaced with the following:

22.12    “Employment Discontinuance” shall mean the termination of employment with an Affiliate, other than in connection with the transfer of employment to another Affiliate, or such other date as required to comply with Legal Deferral Requirements.  A Participant who, in connection with the sale of Metropolitan Property and Casualty Insurance Company to Farmers Group, Inc. that was effective as of April 7, 2021 (the “MPC Closing Date”), had his or her employment transferred to Farmers Group, Inc. or any subsidiary or affiliate thereof, shall be deemed to have an Employment Discontinuance as of that date.  
III.     Section 22.22 shall be replaced with the following:

22.22    “MetLife Companies” shall mean MetLife Group, Inc.; Metropolitan Property and Casualty Insurance Company; SafeGuard Health Plans, Inc. (of California); and Brighthouse Services, LLC.  Brighthouse Services, LLC shall be a MetLife Company solely for the period beginning October 1, 2016 and ending December 31, 2016.  Effective January 1, 2017, Brighthouse Services, LLC will no longer be a MetLife Company.  Effective April 8, 2021, Metropolitan Property and Casualty Insurance Company will no longer be a MetLife Company.

Page 1 of 2

IN WITNESS WHEREOF, this Amendment Number Fourteen to the MetLife Leadership Deferred Compensation Plan is hereby adopted and approved.

By: __/s/ Andrew Bernstein_________________________
PLAN ADMINISTRATOR

Date: __April 7, 2021

Witness___/s/ Celia Donald_________________________
Page 2 of 2Document

Exhibit 10.27.12

AMENDMENT NUMBER TEN TO THE

METLIFE PLAN FOR TRANSITION ASSISTANCE FOR GRADES 14 AND ABOVE

(Amended and Restated Effective April 1, 2014)

THE METLIFE PLAN FOR TRANSITION ASSISTANCE FOR GRADES 14 AND ABOVE (the “Plan”) is hereby amended, effective January 1, 2021, as follows:

The definition of “Salary” in Section 1.4.17 is hereby amended to add the following paragraph at the end of the definition to read as follows:
“Notwithstanding anything to the contrary ,“Salary” shall under no circumstances include amounts received:  (a) pursuant to the MetLife Carried Interests Program; or (b) pursuant to any compensation system or program where payments are made to an Employee because of direct or indirect services such Employee provides toward certain commingled funds managed by MetLife Investment Management (“MIM”) or any successor organization, where the payment itself for such services is based upon how much such MIM-managed commingled funds earns in profit or fees.”

IN WITNESS WHEREOF, the Company has caused this Amendment to be adopted this 23rd day of December 2020.

METLIFE GROUP, INC.

/s/ Andrew Bernstein______________
Andrew Bernstein, Plan Administrator

Witness: /s/ Karen Hinkson_________Document

Exhibit 10.27.13

AMENDMENT NUMBER ELEVEN TO THE
METLIFE PLAN FOR TRANSITION ASSISTANCE FOR GRADES 14 AND ABOVE
(Amended and Restated Effective April 1, 2014)
THE METLIFE PLAN FOR TRANSITION ASSISTANCE FOR GRADES 14 AND ABOVE (the “Plan”) is hereby amended, effective March 1, 2021, as follows:
The definition of “Service” in Section 1.4.20 is hereby amended to add the following paragraph at the end of the definition to read as follows:
“Notwithstanding anything to the contrary, effective March 1, 2021, for the avoidance of doubt, service earned at Versant Health, Inc. (including service earned at Versant Health, Inc. before Versant Health, Inc. became an Affiliate) by Former Versant Employees (as defined in the MetLife Welfare Benefit Plans) shall be added to the Service earned by such Former Versant Employees after such Former Versant Employee becomes an Employee of a Participating Employer (as defined under the MetLife Options and Choices Plan) in determining the total Service such Employee has earned.”
IN WITNESS WHEREOF, the Company has caused this Amendment to be adopted this __3rd_ day of March 2021.
METLIFE GROUP, INC.

/s/ Andrew Bernstein             
Andrew Bernstein, Plan Administrator

Witness: /s/ Celia Donald        
Page 1 of 1Document

Exhibit 10.27.14

AMENDMENT NUMBER TWELVE TO THE
METLIFE PLAN FOR TRANSITION ASSISTANCE FOR GRADES 14 AND ABOVE
(Amended and Restated Effective April 1, 2014)
THE METLIFE PLAN FOR TRANSITION ASSISTANCE FOR GRADES 14 AND ABOVE (the “Plan”) is hereby amended, effective as the closing date of the Stock Purchase Agreement between MetLife Group, Inc. and Farmer’s Group, Inc., dated December 11, 2020 (the “Agreement”), which is April 7, 2021, to clarify the treatment of severance under the Plan related to the Agreement; and, effective March 1, 2021, to correct a scrivener’s error in Amendment #11 to the Plan, as follows:
1.    Effective April 7, 2021, Section 1.4.09 of the Plan is hereby amended, by adding the following new subsection (j) to read as follows:
“(j)    Notwithstanding any provision of this Section 1.4.09 of the Plan to the contrary and in accordance with and subject to Section 8.4 of the Plan, “Employee” shall not include any employee who is defined as a “Farmer’s Employee” in Section 8.4 of the Plan.”
2.    Effective March 1, 2021, Amendment #11 is hereby amended to change the reference to “Service” from Section 1.4.20 to Section 1.4.19.
3.    Effective April 7, 2021, new Section 8.4 of the Plan is hereby added to read as follows:
“§8.4    Sale of the MetLife Property and Casualty Company
(a)Notwithstanding any other provision of the Plan, an Employee at Grade 14 or above who is offered employment by the Buyer as part of the Stock Purchase Agreement between MetLife Group, Inc. and Farmer’s Group, Inc. dated December 11, 2020 (the “Agreement”) whose closing date is April 7, 2021, where the Buyer is defined in such Agreement, regardless of whether such Employee actually becomes an employee of the Buyer, (hereinafter called a “Farmer’s Employee”) shall be deemed to not satisfy the definition of a Job Elimination under Section 1.4.11 of  the Plan.

(b)No Farmer’s Employee shall be granted Severance Pay on account of the transfer of employment to the Buyer.

(c)Notwithstanding any other provision of the Plan, in the event that the Agreement referenced in Section 8.4(a) does not close and the sale does not occur, this entire Section 8.4 shall be null and void.”

Page 1 of 2

IN WITNESS WHEREOF, the Company has caused this Amendment to be adopted this 7th day of April 2021.

METLIFE GROUP, INC.

_/s/ Andrew Bernstein_______________________
Andrew Bernstein, Plan Administrator

Witness:__/s/ Celia Donald___________________

Page 2 of 2Document

Exhibit 10.27.15

AMENDMENT NUMBER THIRTEEN TO THE
METLIFE PLAN FOR TRANSITION ASSISTANCE FOR GRADES 14 AND ABOVE
(Amended and Restated Effective April 1, 2014)
THE METLIFE PLAN FOR TRANSITION ASSISTANCE FOR GRADES 14 AND ABOVE (the “Plan”) is hereby amended, effective as April 12, 2021 to change the Plan Administrator from Andrew Bernstein to Judith Eidenberg Rubinstein:
Effective April 12, 2021, Section 3.2 of the Plan is hereby amended, by adding the following new sentence at the end of the section read as follows:
“Effective April 12, 2021, Andrew Bernstein, the Employee Benefits Committee designate as Plan Administrator for the MetLife Welfare Benefits Plan, the parent plan, of which this Plan is a Constituent Plan, designates Judith Eidenberg Rubinstein as the Plan Administrator of the Plan.”

IN WITNESS WHEREOF, the Company has caused this Amendment to be adopted this 30th day of April 2021.

METLIFE GROUP, INC.

/s/ Andrew Bernstein_____________
Andrew Bernstein, Plan Administrator

Witness: /s/ Danielle Hodorowski_____
Page 1 of 1Exhibit 4.2

 

THIS INSTRUMENT AND ANY SECURITIES ISSUABLE PURSUANT
HERETO HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE ISRAELI
SECURITIES LAW 5728 – 1968, AS AMENDED OR UNDER THE SECURITIES LAWS OF CERTAIN STATES OR FOREIGN SECURITIES LAWS. THESE SECURITIES
MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED IN THIS SAFE AND UNDER THE ACT AND APPLICABLE
STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN EXEMPTION THEREFROM.

 

Wearable
Devices Ltd (Israeli Corporate No. 515056117)

 

SAFE 

(Simple Agreement for Future Equity)

 

THIS CERTIFIES THAT in exchange
for the payment by [Investor’s Name] (the “Investor”) of [US$_______] (the “Purchase Amount”)
on or about [Date], as part of an investment round involving other Safes in the total amount of up to US$3,000,000, Wearable
Devices Ltd (the “Company”) to the Company’s bank account as specified in Exhibit A
on or prior to [____], 202[1] (the “Effective Date”), hereby issues to the Investor the right to certain shares of
the Company’s share capital, subject to the terms set forth below.

 

The “Discount Rate”
is 80% (i.e., 20% discount).

 

See Section 2 for certain
additional defined terms.

 

1. Events

 

(a) Equity Financing.
If there is an Equity Financing before the expiration or termination of this instrument, the Company will automatically issue to the Investor
a number of Safe Shares equal to the Purchase Amount divided by the Conversion Price.

 

In connection with the issuance
of Safe Shares by the Company to the Investor pursuant to this Section 1(a), the Investor will execute and deliver to the Company all
transaction documents related to the Equity Financing; provided, that such documents are the same documents to be entered into
with the purchasers of Standard Shares, with appropriate variations for the Safe Shares if applicable, and provided further, that
such documents have customary limitations, including without limitations, any lock-up or other rights and limitations applicable to the
Investor.

 

(b) Liquidity Event.
If there is a Liquidity Event before the expiration or termination of this instrument, the Investor will, at its option, either (i) receive
a cash payment equal to the Purchase Amount (subject to the following paragraph) or (ii) automatically receive from the Company a number
of Ordinary Shares equal to a fraction, the numerator of which is the Purchase Amount and the denominator of which is the Liquidity Price
multiplied by the Discount Rate, if the Investor fails to select the cash option; provided however, that in connection with an Initial
Public Offering, the Company may condition the issuance of such shares subject to executing and delivering a lock-up agreement in a form
and for a period acceptable to the underwriters of such Initial Public Offering in respect of such shares. The Company shall be entitled,
in its absolute discretion, to refrain from issuing any shares in uncertificated form to the Investor until the expiry of the applicable
lock-up period set out in the required lock-up agreements, even if not signed by the Investor, and shall instead issue to the Investor
a certificate in respect of such shares which includes a legend referring to the lock-up applicable thereto.

 

In connection with Section
(b)(i), the Purchase Amount will be due and payable by the Company to the Investor immediately prior
to, or concurrent with, the consummation of the Liquidity Event. If there are not enough funds to pay the Investor and
holders of other Safes (collectively, the “Cash-Out Investors”) in full, then all of the Company’s
available funds will be distributed with equal priority and pro rata among the Cash-Out Investors in proportion to their
Purchase Amounts, and the Cash-Out Investors will automatically receive the number of Ordinary Shares equal to the remaining unpaid
Purchase Amount divided by the Liquidity Price. In connection with a Change of Control intended to qualify as a tax-free
reorganization, the Company may reduce, pro rata, the Purchase Amounts payable to the Cash-Out Investors by the amount
determined by its board of directors in good faith to be advisable for such Change of Control to qualify as a tax-free
reorganization for U.S. federal income tax purposes, and in such case, the Cash-Out Investors will automatically receive the number
of Ordinary Shares equal to the remaining unpaid Purchase Amount divided by the Liquidity Price.

 

     

     

    

 

(c) Dissolution Event.
If there is a Dissolution Event before this instrument expires or terminates, the Company will pay an amount equal to the Purchase Amount,
due and payable to the Investor immediately prior to, or concurrent with, the consummation
of the Dissolution Event. The Purchase Amount will be paid prior and in preference to any Distribution of any of the assets of the Company
to holders of outstanding Share Capital by reason of their ownership thereof. If immediately prior
to the consummation of the Dissolution Event, the assets of the Company legally available for distribution to the Investor and
all holders of all other Safes (the “Dissolving Investors”), as determined in good faith by the Company’s board
of directors, are insufficient to permit the payment to the Dissolving Investors of their respective Purchase Amounts, then the entire
assets of the Company legally available for distribution will be distributed with equal priority and pro rata among the Dissolving Investors
in proportion to the Purchase Amounts they would otherwise be entitled to receive pursuant to this Section 1(c).

 

(d) Termination.
This instrument will expire and terminate (without relieving the Company of any obligations arising from a prior breach of or non-compliance
with this instrument) upon either (i) the issuance of shares to the Investor pursuant to Section 1(a) or Section 1(b)(ii); or (ii) the
payment, or setting aside for payment, of amounts due the Investor pursuant to Section 1(b)(i) or Section 1(c).

 

2. Definitions

 

“Share Capital”
means the share capital of the Company at the applicable time, including, without limitation, the “Ordinary Shares,” or any
other shares issued by the Company.

 

“Change of Control”
means (i) a transaction or series of related transactions in which any “person” or “group” (within the meaning
of Section 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended), becomes the “beneficial owner” (as defined
in Rule 13d-3 under the Securities Exchange Act of 1934, as amended), directly or indirectly, of more than 50% of the outstanding voting
securities of the Company having the right to vote for the election of members of the Company’s board of directors, (ii) any
reorganization, merger or consolidation of the Company, other than a transaction or series of related transactions in which the holders
of the voting securities of the Company outstanding immediately prior to such transaction or series of related transactions retain, immediately
after such transaction or series of related transactions, at least a majority of the total voting power represented by the outstanding
voting securities of the Company or such other surviving or resulting entity or (iii) a sale, lease or other disposition of all or
substantially all of the assets of the Company.

 

“Change of Control Price”
means the price per one Ordinary Share of the Company at the closing of a Change of Control transaction of the Company as explicitly set
forth in the Change of Control transaction documents (and/or in any exhibits or schedules thereof).

 

If the price per one Ordinary
Share is not explicitly set forth in the Change of Control transaction documents then the price shall be calculated based on the number,
as of immediately prior to the Change of Control, of the Share
Capital (on an as-converted basis) outstanding, assuming exercise or conversion of all outstanding vested and unvested options, warrants
and other convertible securities, but excluding: (i) Ordinary Shares reserved and available for future grant under any
equity incentive or similar plan; (ii) this instrument; (iii) other Safes; and (iv) convertible promissory notes.

 

    2 

     

    

 

“Conversion Price”
means a price per one share of the Standard Shares sold in the Equity Financing multiplied by the Discount Rate, but in no event less
than $2.251793 per one Ordinary Share, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations
and other similar transactions of the Ordinary Shares that occur after the date hereof.

 

If the price per one share of
the Standard Shares sold in the Equity Financing is not explicitly set forth in the Equity Financing agreement (and/or in any of its
exhibits and schedules), then the price per one share of the Standard Shares sold in the Equity Financing shall be calculated based on
the sum, as of immediately prior to the Equity Financing, of: (1) all shares comprising the Company’s Share Capital
(on an as-converted basis) issued and outstanding, assuming exercise or conversion of all outstanding vested and unvested options, warrants
and other convertible securities, but excluding (A) this instrument, (B) all other Safes, and (C) convertible promissory
notes, if any; and (2) all Ordinary Shares reserved and available for future grant under any equity incentive or similar plan of the
Company, and/or any equity incentive or similar plan to be created or increased in connection with the Equity Financing.

 

“Distribution”
means the transfer to holders of the Share Capital by reason of their ownership thereof of cash or other property without consideration
whether by way of dividend or otherwise, other than dividends on Ordinary Shares payable in Ordinary Shares, or the purchase or redemption
of Share Capital by the Company or its subsidiaries for cash or property other than: (i) repurchases of Ordinary Shares held by employees,
officers, directors or consultants of the Company or its subsidiaries pursuant to an agreement providing, as applicable, a right of first
refusal or a right to repurchase shares upon termination of such service provider’s employment or services; or (ii) repurchases
of Share Capital in connection with the settlement of disputes with any shareholder.

 

“Dissolution Event”
means (i) a voluntary termination of operations, (ii) a general assignment for the benefit of the Company’s creditors or (iii) any
other liquidation, dissolution or winding up of the Company (excluding a Liquidity Event), whether voluntary or involuntary.

 

“Equity Financing”
means a bona fide transaction or series of transactions with the principal purpose of raising capital in an aggregate amount of at least
US$ 5,000,000 (excluding all outstanding (i) SAFEs, and (ii) other convertible securities, if any), pursuant to which the Company issues
and sells Shares at a fixed pre-money valuation.

 

“Initial Public Offering”
means the closing of the Company’s first firm commitment underwritten initial public offering of Ordinary Shares on a Trading Market
pursuant to a registration statement filed under the Securities Act (or under any other applicable securities laws).

 

“Initial Public Offering
Price” means the price per one Ordinary Share of the Company at the closing of initial public offering of the Ordinary Shares
of the Company, registered pursuant to an effective registration statement under the Securities Act, or the securities laws of another
jurisdiction as determined by the Company’s Board of Directors, and resulting in the listing of the Ordinary Shares on a Trading Market
(which shall not include any market operated by OTC Markets, Inc.)

 

“Liquidity Event”
means a Change of Control or an Initial Public Offering.

 

“Liquidity Price”
means the price per share equal to the Change of Control Price or the Initial Public Offering Price, as applicable.

 

“Ordinary Shares”
means the ordinary shares of the Company, par value NIS 0.01 per share, and any other class of securities into which such securities may
hereafter be reclassified or changed.

 

    3 

     

    

 

“Safe” means
an instrument containing a future right to Share Capital, similar in form and content to this instrument, purchased by investors for the
purpose of funding the Company’s business operations.

 

“Safe Shares”
means the Share Capital issued to the Investor in an Equity Financing, having the identical rights, privileges, preferences and restrictions
as the shares of the Standard Shares, other than with respect to: (i) if applicable, the conversion price, which will be equal the Conversion
Price; and (ii) if applicable, the basis for any dividend rights, which will be based on the Conversion Price.

 

“Standard Shares”
means the most senior Share Capital issued to the investors investing new money in the Company in connection with the closing of the Equity
Financing.

 

“Trading Market” means any of the following markets or exchanges
on which the Ordinary Shares is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the
Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange (or any successors to any of the foregoing), the Tel
Aviv Stock Exchange, or any other recognized stock exchange on which the Company’s securities shall be registered for trade.

 

3. Company Representations

 

(a) The Company is a corporation
duly organized, validly existing and in good standing under the laws of the state of its incorporation, and has the power and authority
to own, lease and operate its properties and carry on its business as now conducted.

 

(b) The execution, delivery and
performance by the Company of this instrument is within the power of the Company, and, other than with respect to the actions to be taken
when equity is to be issued to the Investor, has been duly authorized by all necessary actions on the part of the Company. This instrument
constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except
as limited by bankruptcy, insolvency or other laws of general application relating to or affecting the enforcement of creditors’
rights generally and general principles of equity. To the knowledge of the Company, it is not in violation of (i) its current articles
of association, (ii) any material statute, rule or regulation applicable to the Company or (iii) any material indenture or contract to
which the Company is a party or by which it is bound, where, in each case, such violation or default, individually, or together with all
such violations or defaults, could reasonably be expected to have a material adverse effect on the Company.

 

(c) The performance and consummation
of the transactions contemplated by this instrument do not and will not: (i) violate any material judgment, statute, rule or regulation
applicable to the Company; (ii) result in the acceleration of any material indenture or contract to which the Company is a party
or by which it is bound; or (iii) result in the creation or imposition of any lien upon any property, asset or revenue of the Company
or the suspension, forfeiture, or nonrenewal of any material permit, license or authorization applicable to the Company, its business
or operations.

 

(d) No consents or approvals are
required in connection with the performance of this instrument, other than: (i) the Company’s corporate approvals; (ii) any qualifications
or filings under applicable securities laws; and (iii) necessary corporate approvals for the authorization of Share Capital issuable pursuant
to Section 1.

 

4. Investor Representations

 

(a) The Investor has full legal
capacity, power and authority to execute and deliver this instrument and to perform its obligations hereunder. This instrument constitutes
valid and binding obligation of the Investor, enforceable in accordance with its terms, except as limited by bankruptcy, insolvency or
other laws of general application relating to or affecting the enforcement of creditors’ rights generally and general principles
of equity.

 

(b) The Investor is an accredited
investor as such term is defined in Rule 501 of Regulation D under the Securities Act, and acknowledges and agrees that if not
an accredited investor on the Effective Date, the Company may void this Safe and return the Purchase Amount. The Investor has been advised
that this instrument and the underlying securities have not been registered under the Securities Act, or any state securities laws and,
therefore, cannot be resold unless they are registered under the Securities Act and applicable state securities laws or unless an exemption
from such registration requirements is available. The Investor is purchasing this instrument and the securities to be acquired by the
Investor hereunder for its own account for investment, not as a nominee or agent, and not with a view to, or for resale in connection
with, the distribution thereof, and the Investor has no present intention of selling, granting any participation in, or otherwise distributing
the same. The Investor has such knowledge and experience in financial and business matters that the Investor is capable of evaluating
the merits and risks of such investment, is able to incur a complete loss of such investment without impairing the Investor’s financial
condition and is able to bear the economic risk of such investment for an indefinite period of time. The Investor is not paying, receiving
or otherwise entitled to receive any amount in cash or otherwise with respect to entering into this instrument, which payment constitutes
transaction based compensation under the Securities Exchange Act of 1934, as amended.

 

    4 

     

    

 

5. Warrants

 

Each Investor shall also be issued,
for no additional consideration, a warrant in the form attached hereto as Exhibit B (the “Warrant”), to purchase
additional ordinary shares, NIS 0.01 par value each (“Ordinary Shares”) of the Company (“Warrant Shares”),
for an aggregate amount equal to twenty five percent (25%) of such Investor’s Purchase Amount (“Exercise Amount”), for
an exercise price per Warrant Share which is equal to One Hundred and Fifty Percent (150%) of the Per Share Purchase Price at the IPO
(“Exercise Price”). The Warrant shall be exercisable until the earlier to occur of: (i) Eighteen (18) months from the
Effective Date; or (ii) a Change of Control, defined above (the “Exercise Period”). This Warrant shall, at the end of
the Exercise Period, no longer be exercisable and become null and void.

 

“Per Share Purchase Price
at the IPO” means the price per one Ordinary Share of the Company at the closing of the Company’s Initial Public Offering.

 

6. Miscellaneous

 

(a) Any provision of this instrument
may be amended, waived or modified only upon the written consent of the Company and the Investor.

 

(b) Any notice required or permitted
by this instrument will be deemed sufficient when delivered personally or by overnight courier or sent by email to the relevant address
listed on the signature page, or 48 hours after being deposited in the mail as certified or registered mail with postage prepaid, addressed
to the party to be notified at such party’s address listed on the signature page, as subsequently modified by written notice.

 

(c) The Investor is not entitled,
as a holder of this instrument, to vote or receive dividends or be deemed the holder of Share Capital for any purpose, nor will anything
contained herein be construed to confer on the Investor, as such, any of the rights of a shareholder of the Company or any right to vote
for the election of directors or upon any matter submitted to shareholders at any meeting thereof, or to give or withhold consent to any
corporate action or to receive notice of meetings, or to receive subscription rights or otherwise until shares have been issued upon the
terms described herein.

 

(d) Neither this instrument nor
the rights contained herein may be assigned, by operation of law or otherwise, by either party without the prior written consent of the
other; provided, however, that this instrument and/or the rights contained herein may be assigned without the Company’s consent
by the Investor to any other entity who directly or indirectly, controls, is controlled by or is under common control with the Investor,
including, without limitation, any general partner, managing member, officer or director of the Investor, or any venture capital fund
now or hereafter existing which is controlled by one or more general partners or managing members of, or shares the same management company
with, the Investor; and provided, further, that the Company may assign this instrument in whole, without the consent of the Investor,
in connection with a reincorporation to change the Company’s domicile.

 

(e) In the event any one or
more of the provisions of this instrument is for any reason held to be invalid, illegal or unenforceable, in whole or in part or in
any respect, or in the event that any one or more of the provisions of this instrument operate or would prospectively operate to
invalidate this instrument, then and in any such event, such provision(s) only will be deemed null and void and will not affect any
other provision of this instrument and the remaining provisions of this instrument will remain operative and in full force and
effect and will not be affected, prejudiced, or disturbed thereby.

 

(f) All rights and obligations
hereunder will be governed by the laws of the State of Israel, without regard to the conflicts of law provisions of such jurisdiction.
Any disputes arising under or in relation to this Agreement shall be resolved exclusively by the competent courts located in the city
of Tel-Aviv-Jaffa, Israel.

 

(Signature page follows)

 

    5 

     

    

 

Final for Execution 

 

IN WITNESS WHEREOF, the undersigned have caused this instrument to be duly
executed and delivered.

 

	 	COMPANY:
    
	 	 	 
	 	By: 	Asher
    Dahan    
	 	Title: 	CEO
	 	Address:	Hata’asiya 2, Yokneam Illit, Israel 
	 	Email:	Asher.dahan@wearabledevices.co.il
	 	Signature: 	
	 	 	 
	 	INVESTOR: 
	 	 	 
	 	By:	                        
	 	Title: 	 
	 	Address:	
	 	Email:	 
	 	Signature: 	

 

 

    6 

     

    

 

Exhibit A

 

Details of the Designated Account

 

    7 

     

    

 

Exhibit B

 

THIS WARRANT AND THE SHARES WHICH
MAY BE PURCHASED UPON THE EXERCISE OF THIS WARRANT HAVE BEEN ACQUIRED SOLELY FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAW OF ANY NON-U.S. JURISDICTION. SUCH SECURITIES MAY NOT BE SOLD, OFFERED
FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF SUCH REGISTRATION OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY AND ITS COUNSEL
THAT SUCH SALE, OFFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF THE ACT AND OF
ANY APPLICABLE SECURITIES LAW OF ANY NON-U.S. JURISDICTION UNLESS SOLD PURSUANT TO RULE 144 OF THE ACT OR ANY OTHER SECURITIES LAW OF
A NON-U.S. JURISDICTION.

 

WARRANT TO PURCHASE SHARES

 

OF

 

WEARABLE DEVICES LTD. 

 

January
___, 2022

 

Terms not defined herein shall
have the meaning ascribed to them in the Simple Agreement for Future Equity executed on or around the date hereof (“SAFE”).

 

Wearable Devices Ltd. an Israeli
company, Reg. No. 51-505611-7 (the “Company”), hereby grants to ____________ (the “Holder”) the
right to purchase from the Company during the exercise period set forth in Section 2 below, such number of Ordinary Shares of the Company,
par value NIS 0.01, equal to the quotient of (x) Twenty Five Percent (25%) of the Holder’s Purchase Amount (as defined in the SAFE) divided
by (y) the Exercise Price, as defined below (the “Warrant Shares”), subject to the terms and conditions set forth below
(“Warrant”).

 

1. Exercise Price. The exercise price for each
Warrant Share purchasable hereunder shall be equal to an amount in United Stated Dollars which is One Hundred and Fifty Percent (150%)
of the Per Share Purchase Price at the IPO (as defined in the SAFE), subject to adjustments under Section 6 of this Warrant (the “Exercise
Price”).

 

    8 

     

    

 

2. Term. The Warrants shall be exercisable
until the earlier to occur of: (i) Eighteen (18) months from Effective Date of the SAFE; or (ii) a Change of Control (defined in the SAFE)
(the “Term”).

 

3. Exercise of Warrant. This Warrant may be
exercised in whole or in part on one or more occasions during its Term.

 

a. Exercise for
Cash. The Warrant may be exercised by the surrender of the Warrant to the Company at its principal office together with the Notice
of Exercise annexed hereto as Exhibit A, duly completed and executed on behalf of the Holder.

 

b. Issuance of Shares on Exercise;
Lock-ups. The Company agrees that the Warrant Shares acquired hereunder shall be issued against receipt of the Notice of Exercise
and payment (as provided in Section 3(a) above) and the Holder shall be deemed the record owner of such Warrant Shares as of and from
the close of business on the date on which this Warrant shall be surrendered, together with payment in full. In the event of a partial
exercise, the Company shall concurrently issue to the Holder a replacement Warrant on the same terms and conditions as this Warrant, but
representing the number of Warrant Shares remaining after such partial exercise.

 

In connection with the issuance
of Warrant Shares by the Company to the Holder pursuant to the terms hereof, the Holder may be required to execute and deliver to the
Company all transaction documents related to such Warrant Shares at the time of exercise (e.g., whether related to a Liquidity Event);
provided, that such documents are the same documents to be entered into with the purchasers or holders of Ordinary Shares, with
appropriate variations for the Warrant Shares, if applicable, and provided further, that such documents have customary limitations,
including without limitations, any lock-up requirements or other rights and limitations applicable to the Holder. Without derogating from
the aforesaid, the Company shall be entitled, in its absolute discretion, to refrain from issuing any shares in uncertificated form to
the Holder until the expiry of the applicable lock-up period set out in the required lock-up agreements, even if not signed by the Holder,
and shall instead issue to the Holder a certificate in respect of such shares which includes a legend referring to the lock-up applicable
thereto.

 

c. Conditional Exercise.
In connection with any Change of Control, such exercise may be made conditional upon the completion of such transaction.

 

4. Fractional Interest. No fractional shares
will be issued in connection with any exercise hereunder. In the event of fractional shares, the Company shall round the number of Warrant
Shares issuable upon such exercise up to the nearest whole share.

 

5. Warrant Confers No Rights of Shareholder.
This Warrant does not, by itself, entitle the Holder to any voting rights or other rights as a shareholder of the Company. The Holder
shall not have any rights as a shareholder of the Company with regard to the Warrant Shares prior to actual exercise resulting in the
purchase of any Warrant Shares.

 

    9 

     

    

 

6. Adjustment of Exercise Price and Number of Shares.
The number and kind of securities purchasable initially upon the exercise of this Warrant and the Exercise Price shall be subject to adjustment
from time to time upon the occurrence of certain events, as follows:

 

a. Adjustment for Shares Splits
and Combinations. If the Company at any time or from time to time during the Term effects a subdivision of its outstanding shares,
the number of Warrant Shares issuable upon exercise of this Warrant immediately before the subdivision shall be proportionately increased,
and conversely, if the Company at any time or from time to time combines its outstanding shares, the number of Warrant Shares issuable
upon exercise of this Warrant immediately before the combination shall be proportionately decreased. Any adjustment under this Section
6(a) shall become effective at the close of business on the date the subdivision or combination becomes effective.

 

b. Adjustment for Certain Dividends
and Distributions In the event the Company at any time, or from time to time makes, or fixes a record date for the determination of
holders of its shares entitled to receive a dividend payable in additional shares, or other distribution payable in additional shares,
then and in each such event the number of Warrant Shares issuable upon exercise of this Warrant shall be increased as of the time of such
issuance or, in the event such a record date is fixed, as of the close of business on such record date, by multiplying the number of Warrant
Shares issuable upon exercise of this Warrant by a fraction: (i) the numerator of which shall be the total number of shares issued and
outstanding immediately prior to the time of such issuance or the close of business on such record date plus the number of shares issuable
in payment of such dividend or distribution, and (ii) the denominator of which is the total number of shares issued and outstanding immediately
prior to the time of such issuance or the close of business on such record date; provided, however, that if such record date is
fixed and such dividend is not fully paid or if such distribution is not fully made on the date fixed thereof, the number of Warrant Shares
issuable upon exercise of this Warrant shall be recomputed accordingly as of the close of business on such record date and thereafter
the number of Warrant Shares issuable upon exercise of this Warrant shall be adjusted pursuant to this Section 6(b) as of the time of
actual payment of such dividends or distributions.

 

c. Adjustment for Reclassification,
Exchange and Substitution. If the Warrant Shares issuable upon the exercise of this Warrant are changed into the same or a different
number of shares of any class or classes of shares, whether by recapitalization, reclassification or otherwise (other than a subdivision
or combination of shares or share dividend, provided for elsewhere in this Section), then and in any such event the Holder shall have
the right thereafter to exercise this Warrant into the kind and amount of shares and other securities receivable upon such recapitalization,
reclassification or other change, by holders of the number of shares for which this Warrant might have been exercised immediately prior
to such recapitalization, reclassification or change, all subject to further adjustment as provided herein and under the Company’s
Amended and Restated Articles of Association (“Articles”).

 

d. Reorganization. If at
any time or from time to time there is a capital reorganization of its shares (other than a recapitalization, subdivision, combination,
reclassification or exchange of shares provided for elsewhere in this Subsection), then, as a part of such reorganization, provision shall
be made so that the Holder shall thereafter be entitled to receive upon exercise of this Warrant, the number of shares or other securities
or property of the Company, to which a holder of shares deliverable upon conversion would have been entitled on such capital reorganization.
In any such case (except to the extent any cash or property is received in such transaction), appropriate adjustment shall be made in
the application of the provisions of this Subsection and the Articles with respect to the rights of the Holder after the reorganization
to the end that the provisions of this Subsection (including adjustment of the number of shares of Warrant Shares issuable upon exercise
of this Warrant) shall be applicable after that event and be as nearly equivalent to the provisions hereof as may be practicable.

 

    10 

     

    

 

e. Adjustment of Exercise
Price. Upon each adjustment in the number of Warrant Shares purchasable hereunder, the Exercise Price shall be proportionately increased
or decreased, as the case may be, in a manner that is the inverse of the manner in which the number of Warrant Shares purchasable hereunder
shall be adjusted.

 

f. No Change Necessary; Certain
IPO Adjustments. The form of this Warrant need not be changed due to any adjustment in the Exercise Price or in the number and/or
character of Warrant Shares issuable upon its exercise.

 

g. Other Events. If, while
this Warrant, or any portion hereof, remains outstanding and unexpired, any other event occurs as to which the provisions of this Section
6 do not strictly apply or if strictly applicable would not fairly protect the purchase rights of the Holder in accordance with the provisions
hereof, then the Board shall make an adjustment in the number and class of shares available under the Warrant, the Exercise Price or the
application of such provisions, so as to protect such purchase rights as aforesaid. The adjustment shall be such as will give the Holder
upon exercise for the same aggregate Exercise Price the total number, class and kind of shares as such Holder would have owned had the
Warrant been exercised immediately prior to the event and had the Holder continued to hold such shares until after the event requiring
adjustment.

 

h. General Protection.
The Company will not, by amendment of its Articles or through any reorganization, transfer of assets, consolidation, merger, dissolution,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to
be observed or performed hereunder, but will at all times in good faith assist in the carrying out of all the provisions hereof. The Company
agrees and undertakes that at all times it will maintain and reserve such number of authorized but unissued Warrant Shares so that this
Warrant may be exercised into Warrant Shares immediately pursuant to its terms.

 

7. Notice of Adjustments. Whenever the number
of Warrant Shares purchasable hereunder or the Exercise Price thereof shall be adjusted pursuant to Section 6 hereof, the Company shall
provide notice to the Holder setting forth, in reasonable detail, the event requiring the adjustment, the amount of the adjustment, the
method by which such adjustment was calculated, and the number and class of Warrant Shares which may be purchased and the Exercise Price
therefor after giving effect to such adjustment.

 

8. Notification of Certain Events.
Prior to the expiration of this Warrant pursuant to its terms, in the event that the Company shall authorize:

 

(a) A Change
of Control; or

 

    11 

     

    

 

(b) any transaction
resulting in the expiration of this Warrant (for avoidance of doubt excluding the automatic expiration of the Warrant at the end of the
Term);

 

the Company shall deliver
to the Holder a written notice of the same, at least 7 business days prior to the designated record date of such event.

 

9. Transfer. Neither this Warrant nor any rights
hereunder may be assigned, conveyed or transferred, in whole or in part, without the Company’s prior written consent, other than
to a Permitted Transferee, as defined in the Articles.

 

10. Terms Binding. By acceptance of this
Warrant, the Holder accepts and agrees to be bound by all the terms and conditions of this Warrant

 

11. Representations and Warranties. The Company
represents and warrants to the Holder as follows: (i) all corporate actions on the part of the Company, its officers, directors and shareholders
necessary for the sale and issuance of the Warrant and the Warrant Shares and the performance of the Company’s obligations hereunder were
taken prior to and are effective as of the effective date of this Warrant; (ii) This Warrant has been duly authorized and executed by
the Company and is a valid and binding obligation of the Company enforceable in accordance with its terms; (iii) the Warrant Shares are
duly authorized and reserved for issuance by the Company and, when issued in accordance with the terms hereof, will be validly issued,
fully paid and non-assessable and not subject to any liens, claims, and encumbrances, preemptive rights or similar rights.

 

12. Loss, Theft, Destruction or Mutilation of Warrant.
Upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of any Warrant or
Shares certificate, and in case of loss, theft or destruction, of indemnity, or security reasonably satisfactory to it, and upon reimbursement
to the Company of all reasonable expenses incidental thereto, and upon surrender and cancellation of such Warrant or Shares certificate,
if mutilated, the Company will make and deliver a new Warrant or Shares certificate of like tenor and dated as of such cancellation, in
lieu of such Warrant or Shares certificate.

 

13. Notices. Any notice or other communication
hereunder shall be in writing and shall be deemed to have been given upon delivery, if personally delivered or three business days after
deposit if deposited in the mail for mailing by certified mail, postage prepaid, or on the next business day following transmission and
electronic confirmation of receipt if sent via electronic mail or facsimile, and addressed as follows: if to the Company – at the
Company’s main offices; if to the Holder – at the address set forth opposite its signature below or at such other address
which may be provided hereafter by the Holder to the Company in accordance herewith.

 

14. Governing Law; Jurisdiction. This
Warrant shall be governed by and construed in accordance with the laws of the State of Israel regardless of any applicable conflict of
laws provisions, and the competent courts in Tel-Aviv-Jaffa, Israel shall have the sole and exclusive jurisdiction over all matters arising
in connection with this Warrant.

 

    12 

     

    

 

15. Headings. The headings and captions
used in this Warrant are used for convenience only and are not to be considered in construing or interpreting this Warrant. All references
in this Warrant to sections and exhibits shall, unless otherwise provided, refer to sections hereof and exhibits attached hereto, all
of which exhibits are incorporated herein by this reference.

 

16. Amendment; Waiver; Delay; Cumulative Remedies.
Any term of this Warrant may be amended, and the observance of any term of this Warrant may be waived (either generally or in a particular
instance and either retroactively or prospectively) only with the written consent of the Company and the Holder. No delay or omission
to exercise any right, power or remedy accruing to Holder, upon any breach or default of the Company under this Warrant, shall impair
any such right, power or remedy of Holder nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein,
or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver
of any other breach or default theretofore or thereafter occurring. All remedies, either under this Warrant or by law or otherwise afforded
to any Holder, shall be cumulative and not alternative.

 

17. Entire Agreement. This Warrant constitutes
the entire agreement between the parties hereto with regard to the subject matters hereof, and supersedes any prior communications, agreements
and/or understandings between the parties hereto with regard to the subject matters hereof.

 

18. Taxes. Holder shall bear full responsibility
for all tax obligations and consequences relating to the exercise of this Warrant or the Warrant Shares issuable upon the exercise of
this Warrant, which by their nature apply to holders of warrants.  In the event that the Company is required under applicable law
to withhold any tax as a result of the exercise of this Warrant and/or the issuance of the Warrant Shares, the Company will be entitled
to withhold such taxes in accordance with applicable law, unless the Company is provided with a valid certificate exempting the Company
from, or reducing the due withholding tax in respect of such payment as obtained from the Israeli Tax Authority.

 

[Signatures to Follow]

 

    13 

     

    

 

IN WITNESS WHEREOF, the Company
has signed this Warrant to purchase Warrant Shares as of the date first appearing above.

 

		 
	Wearable Device Ltd.	 
	 	 
	Name:	                            	 
	 	Chief Executive Officer	 
	 	 
	Agreed and Acknowledged:	 
	 	 
		 

 

[Investor’s name]

 

	By: 	 	 

 

Date: _______, 202_

 

Address:

 

[__________]

 

Attn: [__________]

 

Tel:  [__________]

 

Fax: [__________]

 

Email: [__________]

 

[Signature page to Warrant 2021]

 

    14 

     

    

 

NOTICE OF EXERCISE

 

To: Wearable Devices Ltd.

 

	1.	The undersigned hereby elects to purchase _________ Ordinary Shares of Wearable Devices Ltd., pursuant to the terms of the attached Warrant.

 

	2.	Payment. Enclosed is payment / proof of payment of US$ [Exercise Price multiplied by the number of Warrant Shares] in cash.

 

	3.	Please issue a certificate representing said shares in the name of the undersigned. 

 

	4.	Please issue a new Warrant for the unexercised portion (if any) of the attached Warrant in the name of the undersigned.

 

		 	 
	(Date)	 	(Print Name)
	 	 	 
	 	 	 
	 	 	(Signature)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00340-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00340-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00340-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00340-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00340-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00340-of-00352.parquet"}]]